PHARMARON (03759.HK): Completes H-Share Placement, Net Proceeds Approximately HK$1.319 Billion

NewTimeSpace · 2026/01/22 17:13 · By Jiayi Sun

On January 22, PHARMARON announced the completion of its H-share placement. The company placed 58,440,800 new H-shares to no fewer than six independent placees at a price of HK$22.82 per share, raising net proceeds of approximately HK$1.319 billion. The funds will be used for facility construction, debt repayment, and working capital supplementation. Following the placement, the proportion of H-shares in the company’s total issued share capital has increased to 19.28%.

NewTimeSpace News: PHARMARON (03759.HK) disclosed in an announcement on January 22, 2026, that it has fulfilled all placement conditions and completed the H-share placement. Goldman Sachs and HSBC acted as joint global coordinators, among other roles, for the placement, with the issue price set at HK$22.82 per share.

According to the announcement, a total of 58,440,800 new H-shares were placed, generating net proceeds of HK$1.3187 billion. Approximately 70% of the funds will be used to enhance the capabilities and capacity of laboratory services, drug process development, and production facilities; 10% for repaying bank loans and other borrowings to optimize the capital structure; and 20% for supplementing working capital and other general corporate purposes.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

PHARMARON 03759.HK